MARKET WIREYahoo Finance • 12h ago
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This PriceYahoo Finance report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
Why INBX Stock dropped -2.54% Today — RQD Quant Desk Flash
$71.78 -2.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $71.32
Inhibrx Biosciences Inc. (INBX) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.08B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on INBX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Inhibrx Biosciences Inc. (NASDAQ: INBX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $71.78 (-2.54% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBX ranks #1003 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does INBX compare to IMTX and CGEM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INBX carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.09B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, INBX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for INBX?
▼
Per INBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002007919), Inhibrx Biosciences Inc. generated $1.3M in revenue (+550.0% YoY), -$140.1M in net income, and -$129.8M in free cash flow against $146.5M in total assets and $100.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $71.31 (-0.65%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-18% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (18/100 Composite)
🔍 WHY INBX SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+5/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+4/20 pts (22% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$90.53-0.8% Next Q
26
Q2 (-2Q)Grade E$89.79-1.3% Next Q
23
Q3 (-1Q)Grade E$88.61-19% Next Q
21
CurrentGrade E$71.78-12.2% Hist 90D α
18
Trajectory: E (26) → E (18)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a INBX Turnaround Squeeze
While INBX currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($101.74) and Max Pain ($75.37) forces dealer call-delta covering toward $163.05.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INBX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INBX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INBX Stock dropped -2.54% Today — RQD Quant Desk Flash
Inhibrx Biosciences Inc. (INBX) dropped -2.54% to $71.78, trading at 15% of its 52-week range ($57.3 – $155.29). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($57.3 – $155.29) with RSI-14 at 33.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $71.78 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live INBX Headlines & Catalysts
CATALYSTMoomoo • 15h ago
Inhibrx Biosciences Down Over 26%, On Track for Record Percent Decrease -- Data TalkMoomoo report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREPR Newswire • 18h ago
Inhibrx Announces Participation in Upcoming Scientific ConferencesPR Newswire report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 21h ago
Inhibrx CEO Mark Lappe buys over $848k in company stockInvesting.com report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?Yahoo Finance report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
Learn Why The Bull Case For Inhibrx Biosciences Stock Could Change Following Conference Data PresentationsSimply Wall St report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported.Stock Titan report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 5d ago
US Top Movers: Biggest Gainers and Decliners in Today's SessionToday's US market movers: top gainers and decliners ranked by percentage change, with double-digit moves on both sides.
CATALYSTYahoo • 12d ago
Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?Investors are always seeking some new sign, some signal that will indicate the right stock, and the right place or time to invest. They’ll chase after analyst forecasts, macro headlines, and earnings whispers – all the u
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBX)
- ✓Walkthrough of INBX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INBX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.90%📐 HORIZONTAL RANGE
2026-11-02O $73.29H $73.65L $71.78C $71.78VOL 358.8K
RES: $162.7SUP: $62.65SMA50: $101.7SMA200: $92.15
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INBX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on INBX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INBX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INBX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBX)
Health Care Rank #1003 of 1016
⚔️ IMTX vs INBX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INBX vs. IMTX, CGEM, ODTX, PRME)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Inhibrx Biosciences Inc. (INBX) ranks #1003 by composite RQD confidence (18/100, grade E) and #355 by equity capitalization ($1.08B). Within this direct 5-issuer industry benchmark cohort, INBX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with INBX at 18/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INBX
ACTIVE
Inhibrx Biosciences Inc. | E | 18/100 | — | — | -35.0% | -2.54% | $1.08B | Benchmark Subject |
| IMTX Immatics N.V. | D | 45/100 | — | — | — | -1.50% | $1.09B | /imtx-vs-inbx → |
| CGEM Cullinan Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -2.72% | $994.3M | /cgem-vs-inbx → |
| ODTX Odyssey Therapeutics Inc. | D+ | 52/100 | — | — | — | -1.46% | $953.0M | /odtx-vs-inbx → |
| PRME Prime Medicine Inc. | E | 31/100 | — | — | -35.0% | -9.92% | $950.4M | /prme-vs-inbx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002007919In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inhibrx Biosciences Inc. (INBX) reported GAAP revenue of $1.3M (+550.0% vs. FY2024 revenue of $200.0K , and -27.8% cumulative change since FY2023) , GAAP net income of -$140.1M, operating cash flow of -$129.8M, and free cash flow of -$129.8M (+34.1% YoY). On the balance sheet, INBX closed FY2025 with $146.5M in total assets against $100.6M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.3M | -$140.1M | -$129.8M | -$129.8M | $146.5M | $100.6M |
| FY2024 (FY) | 2024-12-31 | $200.0K | $1.69B | -$194.4M | -$197.0M | $180.8M | $0 |
| FY2023 (FY) | 2023-12-31 | $1.8M | -$241.4M | -$193.3M | -$193.3M | — | — |
3. INBX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Inhibrx Biosciences Inc. (NASDAQ: INBX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $71.78 (-2.54% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBX ranks #1003 in composite RQD confidence.
How does INBX compare to IMTX and CGEM in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INBX carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.09B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, INBX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INBX?
Per INBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002007919), Inhibrx Biosciences Inc. generated $1.3M in revenue (+550.0% YoY), -$140.1M in net income, and -$129.8M in free cash flow against $146.5M in total assets and $100.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INBX trading relative to its 50-day, 200-day, and 52-week technical levels?
INBX last traded at $71.78 (-2.54% on volume of 438,874 shares), positioning the stock -29.45% below its 50-day simple moving average ($101.74) and -22.11% below its 200-day simple moving average ($92.15). Across its 52-week range of $57.30 to $155.29, INBX sits at the 14.8% percentile with a 14-day RSI of 33.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($62.81 to $80.75).
INBX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INBX stock moving today?
Why INBX Stock dropped -2.54% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 18/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
INBX — Inhibrx Biosciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:51Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating is 18, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across its five pillars (each scored out of 20), the rating shows weakness throughout:
- Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -11.98%. For a prospective investor, this means the business is not currently generating returns on invested capital, and free cash flow is negative relative to the market value.
- Whale 13F Flow: 4 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The low score signals weak institutional support in the source data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider conviction signals in the data.
- Macro Regime Fit: 3 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock moves in line with the broad market by this measure; the low score reflects weak fit with the current regime per the rating.
- Forensic Balance Sheet: 3 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 8.5. These readings point to elevated financial distress risk as measured by the rating.
Taken together, the rating frames the stock as high-risk on a fundamental and forensic basis. Any upside a prospective investor considers would have to come from factors outside the cash-flow and balance-sheet measures, which the source data does not otherwise develop. The rating's verdict is "Avoid."
Business
Inhibrx Biosciences Inc. (INBX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, it has a market capitalization of $1.1B. The source data does not describe its products, customers, or revenue model beyond reported revenue figures in the financials section.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1.3M | $-135.0M | $-140.1M | N/A | $-129.8M | $124.2M | $100.6M |
| FY 2024 | $0.2M | $-331.4M | $1687.6M | N/A | $-197.0M | $152.6M | $0.0M |
| FY 2023 | $1.8M | $-219.2M | $-241.4M | N/A | $-193.3M | N/A | N/A |
Per the SEC financials, operating losses appear in every reported period, and FY 2025 net margin and operating margin are both -60% per the market data. Gross margin is 0%. ROIC is -35%, and the Roarable RQD rating cites an Altman Z-Score of 0.2 and a Piotroski F-Score of 3/9. Per the Roarable RQD rating, Debt/Equity is 8.5. The FY 2024 net income figure of $1687.6M is positive while operating income is -$331.4M; the source data does not explain this divergence.
Recent Catalysts & News Wire Analysis
Recent news items in the source data, all relating to INBX:
- Market action: A report on INBX stock "looking hard to pin down" at its current price (marked YELLOW, MARKET WIRE).
- Price decline (GREEN, CATALYST): A Moomoo headline states the stock is "Down Over 26%, On Track for Record Percent Decrease."
- Conference participation (YELLOW, MARKET WIRE): A PR Newswire release announces participation in upcoming scientific conferences.
- Insider purchase (YELLOW, MARKET WIRE): An Investing.com headline reports that the CEO bought over $848k in company stock.
- Pipeline credibility (YELLOW, MARKET WIRE): A Yahoo Finance piece questions whether global data reframes the late-stage pipeline credibility.
- Conference data presentations (GREEN, CATALYST): A Simply Wall St piece discusses how the bull case could change following conference data presentations.
The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals. The source data does not specify the content of the pipeline data, conference presentations, or the nature of the late-stage pipeline.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply chain is "NONE," with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. A prospective investor should note that the absence of mapped dependencies means second-order ripple effects cannot be assessed from the provided sources. The conference data and pipeline items in the news flow are the main points to monitor for any read-through, but the source data does not connect them to specific counterparties.
Open Questions
- What are the specific pipeline assets, indications, and data results referenced in the late-stage pipeline and conference headlines?
- What explains the FY 2024 net income of $1687.6M alongside an operating loss of $331.4M, and what are the drivers of the FY 2025 $100.6M debt position?
- What is the cash runway implied by FY 2025 cash of $124.2M against FCF of $-129.8M?
- What are the P/E, EPS, and EV/EBITDA values once earnings are positive, if ever, given the EPS field is N/A across reported periods?
- Who are the holders behind the 13F, Form 4, and Congressional flows the rating references, and what are their positions?
INBX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Inhibrx Biosciences Inc. (INBX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 12h ago
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price Yahoo Finance report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Moomoo • 15h ago
Inhibrx Biosciences Down Over 26%, On Track for Record Percent Decrease -- Data Talk Moomoo report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE PR Newswire • 18h ago
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 21h ago
Inhibrx CEO Mark Lappe buys over $848k in company stock Investing.com report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility? Yahoo Finance report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
Learn Why The Bull Case For Inhibrx Biosciences Stock Could Change Following Conference Data Presentations Simply Wall St report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported. Stock Titan report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session Benzinga report covering Inhibrx Biosciences Inc. (INBX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
INBX Bull vs. Bear Conversation Board — What's Your Call at $71.78?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INBX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $64.81 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is INBX (E • RQD 18/100) a Buy at $73.65?
Welcome to the INBX (Inhibrx Biosciences Inc.) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $58.92 (-20.0%)
Spot @ $73.65 Pump the brakes on INBX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on INBX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Inhibrx Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $90.59 (+23.0%)
Spot @ $73.65 INBX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on INBX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $73.65 (52-wk range $57.30 - $155.29), any beat on forward guidance forces shorts and underweight funds to chase.